Birth after preeclamptic pregnancies: association with allergic sensitization and allergic rhinoconjunctivitis in late childhood; a historically matched cohort study

Table 2 Atopy, asthma and lung function in late childhood in 586 Norwegian children according to mother’s preeclampsia status

	Severe preeclampsia			Mild/moderate preeclampsia			No preeclampsia			Severe vs. no preeclampsia	Mild/moderate vs. no preeclampsia	Overall
Outcome variable	n			n			n			p-value^a)	p-value^a)	p-value^b)
FU1 variables
Allergic rhinoconjunctivitis, n (%)	54	19	(35.2)	161	36	(22.4)	371	71	(19.1)	0.018	0.822	0.015
Atopic dermatitis, n (%)	54	15	(27.8)	163	37	(22.7)	369	92	(24.9)	1.476	1.172	1.000
Asthma, n (%)	53	9	(17.0)	161	14	(8.7)	366	30	(8.2)	0.092	1.730	0.100
FU2 variables
Allergic sensitization, n (%)	39	15	(38.5)	112	40	(36.3)	230	72	(31.3)	0.918	0.924	0.296
High level allergic sensitization, n (%)^c)	39	15	(38.5)	112	28	(25.0)	230	50	(21.7)	0.056	1.166	0.042
Current asthma, n (%)	46	6	(13.0)	123	12	(9.8)	279	19	(6.8)	0.454	0.630	0.126
FEV₁%, mean, 95% CI	45	89.7	(87.0, 92.5)	126	91.0	(89.0, 93.0)	272	91.1	(90.0, 92.2)	1.000	1.000	0.682
FVC%, mean, 95% CI	45	99.2	(95.5, 102.8)	126	100.0	(97.7, 102.3)	272	101.1	(99.8, 102.4)	0.965	1.000	0.489
FEV₁/FVC, mean, 95% CI	45	84.6	(82.7, 86.5)	126	85.3	(83.9, 86.6)	272	84.9	(84.1, 85.7)	1.000	1.000	0.482
FEF_25–75%, mean, 95% CI	45	84.9	(79.4, 90.3)	126	89.6	(85.9, 93.4)	272	87.4	(85.1, 89.6)	1.000	0.827	0.317
FEF_25–75/FVC, mean, 95% CI	45	54.5	(50.0, 59.0)	126	57.3	(54.7, 59.9)	272	55.7	(54.1, 57.4)	1.000	0.906	0.429

Abbreviations: FU1 first follow-up at the ages of 10.8 years (girls) and 11.8 years (boys), FU2 second follow-up at the age of 12.8 years (both genders), FEV ₁ % forced expiratory volume in first second predicted, CI Confidence interval, FVC% forced vital capacity predicted, FEF _25–75 % forced expiratory flow between 25% and 75% of the forced vital capacity, predicted.
^a)Pearson’s exact chi-square test (dichotomous variable) and one way analysis of variance (continuous variable) with Bonferroni corrections;
^b)Cochran-Armitage test for dichotomous outcomes and one way analysis of variance for continuous outcomes;
^c)Sum of specific IgE > 3.9 kU/l.

ISSN: 1471-2431